World's First Pig-to-Living-Human Liver Transplant Survives 171 Days
A 10-gene-edited pig liver was transplanted into a living human for the first time, functioning for 31 days before removal due to a novel complication.
Summary
Researchers in China performed the world's first auxiliary pig-to-living-human liver xenotransplantation using a pig liver with 10 genetic modifications. The organ was transplanted into a patient with inoperable liver cancer, serving as a bridge toward human liver transplantation. The pig liver functioned normally for 31 days with no rejection or infection. On day 38, the liver was surgically removed after a newly documented complication called xenotransplantation-associated thrombotic microangiopathy (xTMA) emerged. This complication was successfully treated with the drug eculizumab and plasma exchange. The patient ultimately died on day 171 from repeated gastrointestinal bleeding unrelated to the xenograft itself. The case establishes proof-of-concept for pig liver transplantation in living humans and identifies xTMA as a critical hurdle for the field to overcome.
Detailed Summary
The global organ shortage kills thousands of patients every year while they wait for a suitable donor. Xenotransplantation — transplanting organs from genetically engineered animals into humans — has long promised a solution, but pig-to-human liver transplantation in a living recipient had never been reported until now.
Researchers at the First Affiliated Hospital of Anhui Medical University, in collaboration with Yunnan Agricultural University, transplanted a genetically modified pig liver as an auxiliary organ into a living patient with a large hepatocellular carcinoma deemed ineligible for curative resection. The donor pig liver carried 10 targeted genetic edits: knockouts of xenoantigen genes that normally trigger catastrophic immune rejection, plus knock-ins of seven human transgenes designed to improve immune and coagulation compatibility.
For the first 31 days post-surgery, the results were remarkable. No hyperacute or acute rejection occurred. The pig liver produced bile, corrected coagulation deficits, and maintained metabolically active liver function. Early post-operative coagulopathy — reflected in elevated D-dimer and fibrin degradation products — was managed successfully with anticoagulant therapy.
On day 38, however, the team identified xenotransplantation-associated thrombotic microangiopathy (xTMA), a potentially catastrophic vascular complication documented here in a living human recipient for the first time. The auxiliary liver was removed, and xTMA was subsequently resolved using eculizumab and plasma exchange. The patient survived 171 days total before dying from recurrent upper gastrointestinal hemorrhage.
This landmark case demonstrates that a 10-gene-edited pig liver can provide clinically meaningful function in a living human without acute rejection. It also identifies xTMA as the primary biological barrier to longer-term success. Future research must focus on refining genetic engineering strategies and prophylactic anti-complement therapies to prevent xTMA and move pig liver xenotransplantation closer to clinical viability.
Key Findings
- World's first pig-to-living-human auxiliary liver transplant achieved 31 days of functional survival without rejection.
- A 10-gene-edited pig liver produced bile, corrected coagulation, and maintained metabolic liver function in a living patient.
- Xenotransplantation-associated thrombotic microangiopathy (xTMA) emerged on day 38, requiring liver removal.
- xTMA was successfully treated with eculizumab and plasma exchange, offering a management roadmap for the field.
- Patient survived 171 days total; death was attributed to gastrointestinal hemorrhage, not xenograft rejection.
Methodology
This was a single-patient case study involving auxiliary pig-to-human liver xenotransplantation using a 10-gene-edited porcine donor organ. Liver function, metabolic markers, coagulation parameters, and immunological indicators were monitored throughout the perioperative period. Histopathological and immunological analyses of xTMA were also performed, representing the first such documentation in a living human recipient.
Study Limitations
This report is based on a single patient case, limiting generalizability and statistical conclusions. The summary is based on the abstract only, as the full paper was not open access. Long-term viability of pig liver xenotransplantation remains unproven, and the patient's death from gastrointestinal hemorrhage prevents assessment of true xenograft longevity.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: